News

The Icahn investigator reviews new data suggesting ethnicity-based differences in molecular phenotype of atopic dermatitis, which may better inform treatment strategies for different populations.

Late-breaking data showed strong results for ruxolitinib cream as a treatment for vitiligo in the long-term extension of the TRuE-V1 and TRuE-V2 studies.

New phase 3 DELTA 1 trial data show the topical pan-JAK inhibitor doubled the rate of treatment success versus vehicle cream.

New late-breaking data showed positive results from the phase 2 trial on a novel septa-specific monoclonal antibody for HS patients.

Dupilumab showed strong results for uncontrolled moderate-to-severe hand and foot atopic dermatitis, meeting its primary and secondary endpoints in the trial.

New long-term extension data from the pivotal TRuE-V program show treatment continuation, as well as post-relapse re-initiation, is efficacious and safe in patients.

In this interview segment, Kwatra describes his upcoming conference presentation on prurigo nodularis and some of the biggest takeaways from his presentation.

After last year's historic approval, investigators want to learn more about their available drug regimens, as well as pediatric eligibility.

Three years into the pandemic, dermatologists have become more confident in discussing vaccine issues with their patients, including the misunderstood risk of disease flare-up associated with boosters.

The University of Toronto expert discusses therapy switching, JAK inhibitor initiation, comorbidity cross-benefit, and more at AAD 2023.

Personalized text message-based smoking cessation intervention was found to be more effective than the non-personalized text message approach, especially among smokers with low nicotine dependence and strong quitting intention.

Amid the introduction of immunosuppressant therapies and the ongoing pandemic, dermatologists find themselves guiding new decisions for patient treatment around vaccinations.

Often overlooked and underfunded, as well as being underpaid compared to internal medicine, it is difficult to convince prospective medical students, many of whom already have substantial debt, to choose a career in pediatric rheumatology.

An interview segment with Lim in which he describes some key takeaways from his conference presentation on sunscreen, photoprotection, and phototherapy.

Little head-to-head data exists between JAK inhibitors and biologics, but common metrics of treatment success can help physicians navigate newer agents.

An investigation utilizing machine learning (Recursive Ensemble Feature Selection, REFS) identifies potential biomarkers for asthma control in pediatric patients.

In his conference presentation ‘Phototherapy and Photoprotection,’ Lim describes some key takeaways and research on UV filter and photoprotection health effects.

The UMass Chan chair of dermatology recaps a historic year of development for the chronic disease, including the progression of even newer treatment options.

Patients with rheumatoid arthritis are at a greater risk of dementia, but why? Take this quiz to test your knowledge of the association between rheumatoid arthritis and dementia.

A systematic review and meta-analysis of 27 studies reveal the prevalence of DR in pediatric T2D increased significantly more than 5 years after diagnosis.

The Mount Sinai Dermatology chair reviews headlines from the 2022 meeting before sharing perspective on developing drugs and topics.

In this interview segment, Damsky spoke more about his conference presentation on JAK inhibitors, describing his response to safety concerns and other information.

In this in-studio episode, hosts offer insight and perspective into what the news regarding the CMS expansion of CGM coverage means for people with diabetes and take a deep dive into a recent announcement of an FDA clearance for Abbott's FreeStyle Libre sensors.

Liver stiffness, body weight, and metabolic risk factors were significantly and comparably reduced in both groups.

Damsky discussed his conference presentation on the application of JAK inhibitors on dermatologic conditions such as granuloma annulare and sarcoidosis.

A phase 2a trial of provides data detailing the effects of inaxaplin, a small molecule APOL1 inhibitor, on urinary protein-to-creatinine ratio in people with focal segmental glomerulosclerosis and two APOL1 variants.

Beyond the obvious benefits, the practice of remote and in-clinic photography is altering treatment capabilities.

The St. Jude oncologist discusses the 30-year development of pediatric melanoma interpretation.

Perfluorohexyloctane eye drops demonstrated significantly superior improvements in tCFS and eye dryness scores at day 57 compared with saline.

The phase 3 DISCOVER-1 and DISCOVER-2 studies were used to evaluate dactylitis resolution in guselkumab-treated patients with psoriatic arthritis through 1 year.